The injectable vial of “Edaravone” with the commercial brand of “ALSAVA” is used for patients with ALS, and its imported sample was formerly provided to patients with extremely higher costs. This product is commercialized by knowledge-based companies and was unveiled in the presence of the vice president for science and technology affairs.

According to the public relations and information center of the Vice-Presidency for science and technology affairs, the product of “ALSAVA” produced and commercialized by Zisttakhmir and Zistdarou knowledge-based companies was unveiled in the presence of Sorena Sattari, the vice president for science and technology affairs.

In the beginning of the ceremony, Sattari expressed his condolences for the passing of passengers of the Ukrainian aircraft, stating: five of the deceased were from the 35,000-member family of the national elites foundation. I had directly talked to two of them, who were supposed to return to Iran and develop their scientific and technological activities with the support of the foundation and the Vice-Presidency.

The president of the national elites foundation added: I sympathize with the families of the deceased since I lost my father in a similar accident and I know the huge burden of this phenomenon on the families of these people. In sympathy with the grieving families, I wish patience.

According to the vice president for science and technology affairs, Arash Pourzarabi, Iman Aghabali, Dr. Mohammad Salehe, Dr. Mohammad Mohammadi Eliasi, and Mohammad Hossein Asadi Lari were some of the elites covered by the national elites foundation. These elites were all graduates of Sharif University of Technology.

Emphasizing the necessity of laying the foundation for developing of knowledge-based businesses to benefit from and support human resources, he continued: our responsibility to maintain and direct our young and creative human capital is heavier than ever. We must work together to correct the improper oil economy that has penetrated the community and the minds of people and society.

Sorena Sattari, the vice president for science and technology affairs

Iran"s Inherent Superiority in Biotechnology in the Region

He mentioned that “biotech” is one of the top priority areas in the ecosystem of knowledge-based economy and that Iran is one of the top region in this technology. In this respect, he continued: we are one of the pioneers in this field in the region and have extensive plans for the development of food products and biological drugs.

Sattari marked: we have an inherent superiority in this area, and there are knowledge-based companies that are capable of recruiting.

Cooperation of drug activists, especially knowledge-based companies that have devoted themselves to recruiting and earning elite staff, has paved the way for the remaining of the elite in the drug field in the country.

A Serious Step towards Securing a One-billion-dollar Drug Import into the Country

In another part of the ceremony, Mostafa Ghanei, the secretary of the biotechnology development headquarter, talked about the program for production of 135 prioritized drugs with the highest level of currency drench, adding: some of these drugs have a currency drench of approximately $570 million. The Vice-Presidency has aimed to reduce the drench of $160 billion with the producing of these products by domestic knowledge-based companies. In addition, $155 billion tomans of support of active knowledge-based companies in this area will lay the foundation for energy saving, occupation creation and formation of added value by domestic production.

He also considered granting facilities, venture capitals and support of knowledge-based companies and use of resources of Iran national innovation fund as solutions to support the production process of these products, expressing: to meet the needs of the country with the full coordination of the Food and Drug Administration, the organization has been assisted in facilitating the process of production of such drugs and has so far received 54 billion Tomans of support.

Mostafa Ghanei, the Secretary of Biotechnology Development Headquarter

From the Supply of Pharmaceutical Raw Materials to the Unveiling of Four Anticancer Drugs

Pointing out that plasma drugs are ranked first in terms of imports, Ghanei added: a knowledge-based company was able to carry out the primary stages of registration of products such as immunoglobulin, human albumin and altplase to enter them into the market in the next spring after clinical tests.

The secretary of biotechnology development headquarter talked about the production of human vaccines with the support of the headquarter and by one knowledge-based company, expressing: pharmaceutical raw materials have been a challenge for pharmaceutical activists in the country, and by the summer of 2015, five more knowledge-based pharmaceuticals will be marketed by knowledge-based companies. We will also unveil four anti-cancer drugs by the end of the year. The norepinephrine tiotropium bromide will also be introduced to the market.

He continued: in the field of poultry vaccines, the drugs in the field are also a priority for production, distributed among knowledge-based companies, and for the first time in the country, about 10 new strains are produced with the support of the Vice-Presidency.

Unveiling ALSAVA Iranian-made Drug by the Vice President for Science and Technology Affairs

 Alleviating the Suffering of Patients by One-tenth the Cost

The Iranian-made injectable vial of “Edaravone” with the commercial name of “ALSAVA” is used for patients with ALS. A high-quality sample of the product is produced inside the country with one-tenth of the cost of its foreign counterpart in order to alleviate pain in patients.

The drug is completely produced inside the country and by Zisttakhmir and Zistdarou companies. The knowledge-based company of Zistdarou produces five important and highly consumed drugs for patients with MS and cancer. This drug has been on the market for a month and reaches the consumer.